Abrocitinib (Cibinqo)
Oral JAK1 selective inhibitor for moderate-to-severe atopic dermatitis
이 치료에 대해
Abrocitinib is a highly selective oral JAK1 inhibitor and innovative JAK inhibitor for atopic dermatitis treatment. JAK1 is a principal mediator of cytokine signaling (IL-4, IL-13, IL-22) involved in Th2 cell differentiation and activation. JAK1 inhibition by abrocitinib effectively suppresses Th2 inflammation, markedly improving skin inflammation, pruritus, and rash in moderate-to-severe atopic dermatitis patients. JAK1 selectivity offers advantages in reduced frequency of side effects such as lipid abnormalities and hematologic changes associated with JAK2 inhibition.
작용 기전
JAK1 is a principal component of cytokine receptor signaling for IL-4Rα, IL-13 receptor, IL-22 receptor and others. IL-4/IL-13 signaling drives Th2 cell differentiation, promoting IgE production, keratinocyte activation, and barrier dysfunction. JAK1 selective inhibition by abrocitinib blocks these signals, suppressing Th2 cell differentiation. Simultaneously, excessive IL-22 production (cytokine involved in skin defense) is suppressed, improving keratinocyte differentiation and epithelial barrier function. JAK1 selectivity minimizes effects on other hematopoietic functions mediated by JAK2 (erythropoiesis, thrombopoiesis), reducing hematologic toxicity.
적응증
기대 효과
EASI score >50% reduction confirmed by 4-8 weeks; marked skin improvement (EASI75+ achievement) reported by 12-16 weeks. Particularly, good complementarity expected with conventional biologics such as dupilumab.
임상 근거
위험 및 부작용
LDL-C elevation reported in ~30%, particularly pronounced with higher doses. Headache and upper respiratory infections mildly reported. Increased infection risk reported but relatively rare. Avoid in patients planning pregnancy.